technetium 99m tc fanolesomab (NeutroSpec)
technetium 99m tc fanolesomab is an FDA-licensed reference biologic from Palatin Technologies, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2004
Reference approved
Reference product
NeutroSpec technetium 99m tc fanolesomab
Palatin Technologies, Inc.
- Approved
- Jul 02, 2004
- Marketing
- Disc
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for technetium 99m tc fanolesomab, in chronological order.
Reference approval
Approval date of the reference technetium 99m tc fanolesomab product.
22 yr 3 mo ago
Frequently asked questions
Are there biosimilars approved for technetium 99m tc fanolesomab (NeutroSpec)?
No 351(k) biosimilars or interchangeable biosimilars referencing technetium 99m tc fanolesomab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.